The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD – Copenhagen, Denmark

Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.

Video navigation menu

The incretin hormone GLP-1 1:32
Mechanisms of GLP-1RAs in reduced glycemia 3:36
Body weight-decreasing effects of GLP-1RAs 4:44
Decreased blood pressure with GLP-1RAs 6:14
GLP-1RAs and lowered blood lipids 7:56

Educational information

This lecture by Filip Krag Knop was part of a CME-accredited symposium "Impacting progression and outcomes of DKD: Translating novel insights with GLP-1 RA to practice" held during ERA EDTA 2019 in Budapest, Hungary.

Faculty

Filip Krag Knop, MD, Professor of endocrinology and Director of Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Denmark

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.

View slides of the presentation